The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2021 Apr 3

PMID 33806113

Citations 16

Authors

Pinelopi I Artemaki

Petros A Letsos

Ioanna C Zoupa

Katerina Katsaraki

Paraskevi Karousi

Sotirios G Papageorgiou

Vasiliki Pappa

Andreas Scorilas

Christos K Kontos

Affiliations

Soon will be listed here.

Abstract

Normal B-cell development is a tightly regulated complex procedure, the deregulation of which can lead to lymphomagenesis. One common group of blood cancers is the B-cell non-Hodgkin lymphomas (NHLs), which can be categorized according to the proliferation and spread rate of cancer cells into indolent and aggressive ones. The most frequent indolent B-cell NHLs are follicular lymphoma and marginal zone lymphoma. MicroRNAs (miRNAs) are small non-coding RNAs that can greatly influence protein expression. Based on the multiple interactions among miRNAs and their targets, complex networks of gene expression regulation emerge, which normally are essential for proper B-cell development. Multiple miRNAs have been associated with B-cell lymphomas, as the deregulation of these complex networks can lead to such pathological states. The aim of the present review is to summarize the existing information regarding the multifaceted role of miRNAs in indolent B-cell NHLs, affecting the main B-cell subpopulations. We attempt to provide insight into their biological function, the complex miRNA-mRNA interactions, and their biomarker utility in these malignancies. Lastly, we address the limitations that hinder the investigation of the role of miRNAs in these lymphomas and discuss ways that these problems could be overcome in the future.

Citing Articles

Exploring the time-dependent regulatory potential of microRNAs in breast cancer cells treated with proteasome inhibitors.

Katsaraki K, Kontos C, Ardavanis-Loukeris G, Tzovaras A, Sideris D, Scorilas A Clin Transl Oncol. 2023; 26(5):1256-1267.

PMID: 38038871 PMC: 11026233. DOI: 10.1007/s12094-023-03349-5.

Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies.

Boutilier A, Huang L, Elsawa S Int J Mol Sci. 2022; 23(19).

PMID: 36232447 PMC: 9569492. DOI: 10.3390/ijms231911145.

The Methylation of the p53 Targets the Genes , , and in the Tumor Tissue of Diffuse Large B-Cell Lymphoma.

Voropaeva E, Pospelova T, Orlov Y, Churkina M, Berezina O, Gurazheva A Genes (Basel). 2022; 13(8).

PMID: 36011313 PMC: 9408007. DOI: 10.3390/genes13081401.

Implication of microRNAs in Carcinogenesis with Emphasis on Hematological Malignancies and Clinical Translation.

Gaal Z Int J Mol Sci. 2022; 23(10).

PMID: 35628648 PMC: 9143361. DOI: 10.3390/ijms23105838.

High Expression of a tRNA Derivative Associates with Poor Survival and Independently Predicts Colorectal Cancer Recurrence.

Tsiakanikas P, Adamopoulos P, Tsirba D, Artemaki P, Papadopoulos I, Kontos C Biomedicines. 2022; 10(5).

PMID: 35625858 PMC: 9138872. DOI: 10.3390/biomedicines10051120.

References

Koralov S, Muljo S, Galler G, Krek A, Chakraborty T, Kanellopoulou C . Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell. 2008; 132(5):860-74. DOI: 10.1016/j.cell.2008.02.020. View

Angelopoulou M . Transformed nodal marginal zone lymphoma versus diffuse large B cell lymphoma: the microRNA aspect. Acta Haematol. 2014; 133(2):212-3. DOI: 10.1159/000365878. View

Culpin R, Proctor S, Angus B, Crosier S, Anderson J, Mainou-Fowler T . A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. Int J Oncol. 2010; 37(2):367-76. DOI: 10.3892/ijo_00000685. View

Moussay E, Wang K, Cho J, Van Moer K, Pierson S, Paggetti J . MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2011; 108(16):6573-8. PMC: 3081030. DOI: 10.1073/pnas.1019557108. View

Lawrie C, Chi J, Taylor S, Tramonti D, Ballabio E, Palazzo S . Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med. 2009; 13(7):1248-60. PMC: 4496139. DOI: 10.1111/j.1582-4934.2008.00628.x. View

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

Krysiak K, Gomez F, White B, Matlock M, Miller C, Trani L . Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017; 129(4):473-483. PMC: 5270390. DOI: 10.1182/blood-2016-07-729954. View

Xiao C, Calado D, Galler G, Thai T, Patterson H, Wang J . MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell. 2007; 131(1):146-59. DOI: 10.1016/j.cell.2007.07.021. View

Gebauer N, Kuba J, Senft A, Schillert A, Bernard V, Thorns C . MicroRNA-150 Is up-regulated in extranodal marginal zone lymphoma of MALT type. Cancer Genomics Proteomics. 2014; 11(1):51-6. View

10.

Lin J, Lwin T, Zhao J, Tam W, Choi Y, Moscinski L . Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia. 2010; 25(1):145-52. PMC: 3083119. DOI: 10.1038/leu.2010.230. View

11.

Craig V, Cogliatti S, Imig J, Renner C, Neuenschwander S, Rehrauer H . Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood. 2011; 117(23):6227-36. PMC: 3790944. DOI: 10.1182/blood-2010-10-312231. View

12.

Zhou B, Wang S, Mayr C, Bartel D, Lodish H . miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A. 2007; 104(17):7080-5. PMC: 1855395. DOI: 10.1073/pnas.0702409104. View

13.

Musilova K, Mraz M . MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia. 2014; 29(5):1004-17. DOI: 10.1038/leu.2014.351. View

14.

Spierings D, McGoldrick D, Hamilton-Easton A, Neale G, Murchison E, Hannon G . Ordered progression of stage-specific miRNA profiles in the mouse B2 B-cell lineage. Blood. 2011; 117(20):5340-9. PMC: 3109709. DOI: 10.1182/blood-2010-10-316034. View

15.

Sagaert X, De Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, Thomas J . Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24(16):2490-7. DOI: 10.1200/JCO.2006.05.6150. View

16.

de Yebenes V, Belver L, Pisano D, Gonzalez S, Villasante A, Croce C . miR-181b negatively regulates activation-induced cytidine deaminase in B cells. J Exp Med. 2008; 205(10):2199-206. PMC: 2556787. DOI: 10.1084/jem.20080579. View

17.

Jeon Y, Lee K, Cho Y, Pugliese A, Kim H, Jeong C . Role of NEK6 in tumor promoter-induced transformation in JB6 C141 mouse skin epidermal cells. J Biol Chem. 2010; 285(36):28126-33. PMC: 2934677. DOI: 10.1074/jbc.M110.137190. View

18.

Sinkovics J . Molecular biology of oncogenic inflammatory processes. I. Non-oncogenic and oncogenic pathogens, intrinsic inflammatory reactions without pathogens, and microRNA/DNA interactions (Review). Int J Oncol. 2011; 40(2):305-49. DOI: 10.3892/ijo.2011.1248. View

19.

Yao Q, Chen Y, Zhou X . The roles of microRNAs in epigenetic regulation. Curr Opin Chem Biol. 2019; 51:11-17. DOI: 10.1016/j.cbpa.2019.01.024. View

20.

Blosse A, Levy M, Robe C, Staedel C, Copie-Bergman C, Lehours P . Deregulation of miRNA in -Induced Gastric MALT Lymphoma: From Mice to Human. J Clin Med. 2019; 8(6). PMC: 6616415. DOI: 10.3390/jcm8060845. View